



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO				Complete If Known	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	09/376,604
Sheet	1	of	2	Filing Date	August 18, 1999
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1642
				Examiner Name	G. B. Nickol
				Attorney Docket Number	AREX-P03-004

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
KAC	AE	US-4,740,371	04-26-1988	St. Remy et al.	
	AF	US-4,879,225	11-07-1989	Morgan Jr. et al.	
	AG	US-5,512,283	04-30-1996	Byers et al.	
	AH	US-5,583,202	12-10-1996	Zanetti	
	AI	US-5,591,593	01-07-1997	Courtenay-Luck	
	AJ	US-5,652,114	07-29-1997	Chu et al.	
	AK	US-5,688,657	11-18-1997	Tsang et al.	
	AL	US-5,869,445	02-09-1999	Cheever et al.	
	AM	US-6,068,830	05-30-2000	Diamandis et al.	
	AN	US-6,077,519	06-20-2000	Storkus et al.	
	AO	US-6,140,091	10-31-2000	Raso et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
					T <sup>6</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
KAC	CP	Chattopadhyay et al., "Human high molecular weight-melanoma associated antigen mimicry by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMel-1," <i>Cancer Res.</i> , 5:6045-51 (1991).			
KAC	CQ	Clark, "Protein Engineering of antibody Molecules for Prophylactic and therapeutic Applications in Man, (monograph), <i>Prot. Eng.</i> , 1 (1993).			
KAC	CR	Crowley et al., "Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins", <i>J. Exp. Med.</i> , 172:383-386 (1990).			
KAC	CS	De la Salle, "Fc <sub>y</sub> R on Human Dendritic Cells", <i>Human IgG Receptors</i> , p. 39-55 (1996).			
KAC	CT	Fagerberg, "Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A," <i>Cancer Imm.</i> , 12:81-87 (1996).			
KAC	CU	Frodin et al., Hybridoma, "Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome—an important antitumoral effector function?", 10:421-31 (1991).			
KAC	CV	Goldenberg et al., "Cancer Diagnosis and Therapy with Radiolabeled Antibodies", In: <i>Immunoconjugates, Antibody Conjugates in Radioimaging and Therapy of Cancer</i> , Vogel. Ed., 259-280 (1987).			
KAC	CW	Keder et al., "Cancer Immunotherapy: Are the results discouraging? Can they be improved?", <i>Adv. Cancer Res.</i> , 59:245-323 (1992).			

Examiner Signature 3198665	/Karen A. Canella, Ph.D./	Date Considered	08/07/2006
-------------------------------	---------------------------	-----------------	------------



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO				<b>Complete If Known</b>	
				Application Number	09/376,604
				Filing Date	August 18, 1999
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1642
				Examiner Name	G. B. Nickol
Sheet	2	of	2	Attorney Docket Number	AREX-P03-004

KAC	CX	Klaus, "Antigen-antibody complexes elicit anti-idiotypic antibodies to self-idiotopes," Nature, 272:265-66 (1978).	
KAC	CY	McGuckin et al., "Circulating tumour-associated mucin concentrations, determined by the CASA assay, in healthy women," Clin. Chim. Acta, 214:139-51 (1993).	
KAC	CZ	Paul, "Factors limiting effective tumor immunity", Fund. Imm., 1163-69 (1993).	
KAC	CA1	Rooijen, "The role of the FDC-retained immune complex network and its dynamics in the activity of germinal centres," Res. Immunol., 144:545-52 (1993).	
KAC	CB1	Sallusto, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor $\alpha$ ," J. Exp. Med., 179:1109-1118 (1994).	
KAC	CC1	Schlom, In: Molecular foundations of Oncology, S. Broder, Ed., Mol. Fndns. Oncol., 105-107 (1991).	
KAC	CD1	Schwartz, "Cancer Markers," In: Cancer: Principles and Practice of Clinical Oncology, 4 <sup>th</sup> Ed., 531-542 (1994).	
KAC	CE1	Tassi et al., "Immunogenicity of anti-idiotypic antibodies and of their F(ab')2 fragments," Imm. Letts., 27:39-44 (1991).	
KAC	CF1	Ward, "Unconjugated antibodies for cancer therapy: lessons from the clinic" Cancer Treatment Rev., 23:305-319 (1997).	
KAC	CG1	Yin et al., "Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer," Int. J. Cancer, 65:406-412 (1996).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature 3199685	/Karen A. Canella, Ph.D./	Date Considered	/Karen A. Canella, Ph.
-------------------------------	---------------------------	-----------------	------------------------



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 669639029 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 25, 2006

Signature:

*Linda Blake*  
(Linda Blake)

Docket No.: AREX-P03-004  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Madiyalakan *et al.*

Application No.: 09/376,604

Confirmation No.: 6693

Filed: August 18, 1999

Art Unit: 1642

For: THERAPEUTIC COMPOSITIONS THAT  
ALTER THE IMMUNE RESPONSE

Examiner: G. B. Nickol

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office ("PTO") is hereby directed to the references listed on the attached PTO/SB/08 (Exhibit A). It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

In a Supplemental Information Disclosure Statement filed May 16, 2005, Applicants directed the Examiner's attention co-pending U.S. Application No. 09/871,339. Applicants would like to direct the Examiner's attention to the claims currently pending in that application (Exhibit B), and to the latest Office Action (Exhibit C) and Advisory Action (Exhibit D) issued by the PTO in that application. It is respectfully requested that the Examiner places his initials immediately following this paragraph to indicate that this information has been considered.

\_\_\_\_\_ (Examiner's Initials)

This Supplemental Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage

3199673\_1

05/31/2006 FFANAEIA 00000019 181945 09376604  
01 FC:1806 180.00 DA

of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Copies of the cited references cited on the attached PTO/SB/08 were previously cited by or submitted to the Patent and Trademark Office U.S. Application No. 09/152,698, which is relied upon in this application for an earlier filing date under 35 U.S.C. §120. In accordance with 37 CFR 1.98(d) copies of these references are not being submitted herewith.

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that this Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. AREX-P03-004. A duplicate copy of this paper is enclosed.

Dated: May 25, 2006

Respectfully submitted,

By   
Gloria Fuentes

Registration No.: 47,580  
ROPES & GRAY LLP  
One International Place  
Boston, Massachusetts 02110-2624  
(617) 951-7000  
(617) 951-7050 (Fax)  
Attorneys/Agents For Applicant

Exhibits A-D